Rhythm Pharmaceuticals 관리
관리 기준 확인 3/4
Rhythm Pharmaceuticals CEO는 David Meeker, Jul2020 에 임명되었습니다 의 임기는 4.33 년입니다. 총 연간 보상은 $ 7.23M, 9.7% 로 구성됩니다. 9.7% 급여 및 90.3% 보너스(회사 주식 및 옵션 포함). 는 $ 10.47M 가치에 해당하는 회사 주식의 0.28% 직접 소유합니다. 10.47M. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 5.4 년입니다.
주요 정보
David Meeker
최고 경영자
US$7.2m
총 보상
| CEO 급여 비율 | 9.7% |
| CEO 임기 | 4.3yrs |
| CEO 소유권 | 0.3% |
| 경영진 평균 재임 기간 | 4yrs |
| 이사회 평균 재임 기간 | 5.4yrs |
최근 관리 업데이트
Recent updates
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$262m |
| Jun 30 2024 | n/a | n/a | -US$261m |
| Mar 31 2024 | n/a | n/a | -US$274m |
| Dec 31 2023 | US$7m | US$705k | -US$185m |
| Sep 30 2023 | n/a | n/a | -US$186m |
| Jun 30 2023 | n/a | n/a | -US$182m |
| Mar 31 2023 | n/a | n/a | -US$181m |
| Dec 31 2022 | US$3m | US$652k | -US$181m |
| Sep 30 2022 | n/a | n/a | -US$181m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$166m |
| Dec 31 2021 | US$6m | US$630k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$15m | US$262k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$146m |
| Dec 31 2019 | US$287k | n/a | -US$141m |
| Sep 30 2019 | n/a | n/a | -US$133m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$282k | n/a | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$268k | n/a | -US$38m |
보상 대 시장: David 의 총 보상 ($USD 7.23M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.56M ).
보상과 수익: 회사가 수익성이 없는 동안 David 의 보상이 증가했습니다.
CEO
David Meeker (70 yo)
4.3yrs
테뉴어
US$7,230,457
보상
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 4.3yrs | US$7.23m | 0.28% $ 10.5m | |
| CFO & Treasurer | 7.3yrs | US$2.31m | 0.16% $ 5.9m | |
| Chief Technical Officer | 4.3yrs | US$1.74m | 0% $ 0 | |
| Executive VP & Head of International | 4.1yrs | US$1.74m | 0.057% $ 2.1m | |
| Executive VP & Head of North America | 4yrs | US$2.11m | 0.0016% $ 58.2k | |
| Corporate Controller | 1.7yrs | 데이터 없음 | 0.0013% $ 47.5k | |
| Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| Senior VP & General Counsel | 4yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Sales & Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | 3.3yrs | 데이터 없음 | 0.022% $ 809.3k | |
| Senior VP & Head of Strategy | 2.8yrs | 데이터 없음 | 데이터 없음 |
4.0yrs
평균 재임 기간
51yo
평균 연령
경험이 풍부한 관리: RYTM 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 9yrs | US$7.23m | 0.28% $ 10.5m | |
| Corporate Controller | 1.7yrs | 데이터 없음 | 0.0013% $ 47.5k | |
| Independent Director | 5.4yrs | US$283.77k | 0.0049% $ 179.8k | |
| Independent Director | 9yrs | US$308.77k | 0.0049% $ 179.8k | |
| Lead Independent Director | 11.7yrs | US$328.77k | 0.014% $ 525.7k | |
| Independent Director | 3.9yrs | US$298.77k | 0.0049% $ 179.8k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.3yrs | US$301.27k | 0.0049% $ 179.8k |
5.4yrs
평균 재임 기간
67yo
평균 연령
경험이 풍부한 이사회: RYTM 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.